Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 10/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23803536 | 0.88 | RIPK1 (0.57) | RIPK1ALDH1A1L3MBTL1LMNAPOLB | |
| SCHEMBL23803560 | 0.84 | RIPK1 (0.52) | RIPK1ALDH1A1L3MBTL1LMNAPOLB | |
| SCHEMBL23819603 | 0.82 | RIPK1 (0.56) | RIPK1ALDH1A1L3MBTL1LMNAPOLB | |
| SCHEMBL17874103 | 0.81 | RIPK1 (0.61) | RIPK1ALDH1A1L3MBTL1LMNAPOLB | |
| SCHEMBL23803515 | 0.80 | RIPK1 (0.60) | RIPK1ALDH1A1L3MBTL1LMNAPOLB | |
| SCHEMBL23803572 | 0.80 | RIPK1 (0.60) | RIPK1ALDH1A1L3MBTL1LMNAPOLB | |
| SCHEMBL23803543 | 0.80 | RIPK1 (0.60) | RIPK1ALDH1A1L3MBTL1LMNAPOLB | |
| SCHEMBL23803516 | 0.79 | RIPK1 (0.58) | RIPK1ALDH1A1LMNAHSD17B10KMT2A | |
| SCHEMBL17882385 | 0.78 | RIPK1 (0.65) | RIPK1ALDH1A1L3MBTL1LMNAKMT2A | |
| SCHEMBL23803540 | 0.78 | RIPK1 (0.53) | RIPK1ALDH1A1L3MBTL1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12129221-B2 | Difluoro phenyl amide RIP1 inhibitor | SIRONAX LTD (KY) | 2024-10-29 | — | — | US | disclosed |
| US-20210284598-A1 | RIP1 Inhibitors | SIRONAX LTD (KY) | 2021-09-16 | — | — | US | disclosed |
| US-20210284598-A1 | RIP1 Inhibitors | SIRONAX LTD (KY) | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284598-A1 | RIP1 Inhibitors | RIPK1, RIPK3, RIPK4 | RIPK1 1/4885ALDH1A1 3847/4885L3MBTL1 1649/4885 |
| US-12129221-B2 | Difluoro phenyl amide RIP1 inhibitor | RIPK1, RIPK3, RIPK4 | RIPK1 1/4885ALDH1A1 3794/4885L3MBTL1 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.